Tirzepatide Peptides for Sale – The Revolutionary Dual GIP/GLP-1 Agonist, 99% Purity

The peptide that transformed metabolic research.

Tirzepatide isn’t just another GLP-1 analog—it represents a fundamental breakthrough in the treatment of type 2 diabetes and obesity . As the first-in-class dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide has demonstrated unprecedented efficacy in clinical trials, with weight loss results rivaling those of bariatric surgery .

What makes tirzepatide unique is its sophisticated molecular engineering. Its structure is primarily based on the GIP amino acid sequence and includes a C20 fatty diacid moiety that prolongs the duration of action, allowing for once-weekly administration . This 39-amino acid synthetic peptide has a greater affinity for the GIP receptor than the GLP-1 receptor, creating a balanced yet potent dual agonism that produces metabolic effects beyond what either receptor activation could achieve alone .

When you’re searching for tirzepatide peptides for sale, you’re looking for a compound with documented effects across multiple research domains. The SURMOUNT clinical trial program has demonstrated that tirzepatide produces mean weight reductions of 15-21% depending on dose, with over 50% of participants achieving ≥20% weight loss at the highest doses . A 2025 systematic review and meta-analysis of 13 RCTs comprising 14,007 participants confirmed dose-dependent weight reductions versus insulin, with the 15 mg dose producing mean differences of -14.5 kg .

At Pinecrest, our tirzepatide:

• Tests at ≥99% purity (HPLC verified)

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

• Molecular Weight: ~4813.45 g/mol

• 39-amino acid synthetic peptide with C20 fatty diacid moiety

• Delivered as lyophilized white powder

• Available in standard research quantities

• Includes batch-specific Certificate of Analysis

• Ships from our China facility to your USA door in 5–7 days

• Backed by our 100% purity guarantee

---

WHAT IS TIRZEPATIDE?

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed for the treatment of type 2 diabetes and obesity . It was discovered by researchers Richard DiMarchi and Matthias Tschöp, whose groundbreaking work in peptide chemistry led to the development of novel gut hormone poly-agonists with unprecedented efficacy . Their discovery was recognized with the Rolf Luft Award in 2026, highlighting the transformative impact of this research .

Molecular Identity

Development and Regulatory Milestones

---

MECHANISM OF ACTION: HOW TIRZEPATIDE WORKS

Dual Receptor Agonism

Tirzepatide’s mechanism of action is fundamentally different from selective GLP-1 receptor agonists. As a dual GIP/GLP-1 receptor agonist, it activates two complementary incretin pathways simultaneously :

Structural Engineering

Tirzepatide’s sophisticated design incorporates several key features :

• GIP-based backbone: The peptide sequence is primarily based on GIP, providing inherent stability and receptor affinity

• C20 fatty diacid moiety: This lipid chain prolongs the duration of action by enabling albumin binding, allowing once-weekly administration

• Balanced receptor activity: Tirzepatide demonstrates greater affinity for GIP receptors but maintains robust GLP-1 activity, creating optimal dual agonism

Beyond Simple Additive Effects

The unprecedented efficacy of tirzepatide cannot be explained by simple additive effects of GIP and GLP-1 activation. Research suggests several unique mechanisms :

GIP Restores Insulinotropic Response: While GIP’s insulinotropic effect is attenuated under hyperglycemic conditions, tirzepatide may enhance the role of GLP-1 and potentially restore GIP’s insulinotropic effect . Studies using GIP receptor antagonists in human islets showed that GIP receptor inhibition consistently reduced tirzepatide’s insulinotropic effect, suggesting GIP receptor activation may be particularly important in humans .

Direct Adipose Tissue Effects: GIP receptors are expressed in adipose tissue, suggesting tirzepatide may directly impact adipose tissue function, contributing to its ability to regulate hyperglycemia and obesity .

Central Nervous System Actions: Both receptors are expressed in brain regions regulating appetite and energy expenditure, with GIP receptor activation potentially amplifying GLP-1’s anorectic effects. Tirzepatide Peptides for Sale

---

CLINICAL EVIDENCE: WHAT THE RESEARCH SHOWS

SURMOUNT Clinical Trial Program

The SURMOUNT trials represent the most comprehensive investigation of tirzepatide for obesity. Key findings include:

2026 Meta-Analysis Findings

A comprehensive systematic review and meta-analysis published in 2026, encompassing 10 RCTs with 6,257 participants, demonstrated :

• Total pooled mean difference vs. placebo: -11.62 kg (95% CI: -14.24 to -9.01, p < 0.001)

• At 15 mg dose:

  • 88.1% achieved ≥5% weight reduction

  • 63.3% achieved ≥10% weight reduction

  • 51.8% achieved ≥15% weight reduction

• Cardiometabolic improvements:

  • Significant reductions in HbA1c, waist circumference, BMI, and lipid profiles

  • Favorable safety profile without increased serious adverse events

SURMOUNT-1 Japanese Subpopulation Analysis (2026)

A prespecified subpopulation analysis of Japanese adults in SURMOUNT-1 published in Obesity (March 2026) showed :

All differences were statistically significant (p < 0.001), with significant improvements in cardiometabolic measures and no new safety concerns .

MC4R Deficiency Model Study (2026)

A February 2026 study published in the International Journal of Obesity evaluated GLP-1 analogs in MC4R-deficient mice—a model of genetic obesity. Key findings included :

• Tirzepatide demonstrated significant anti-obesity effects in this model

• The magnitude and pattern of body-weight reduction were highly consistent with clinical outcomes reported in humans

• Reduction in lean body mass—an adverse effect reported as a clinical risk—was also observed, supporting the translational validity of the model

This research suggests MC4R-deficient mice are a useful preclinical model for obesity pathophysiology associated with impaired MC4R signaling, such as Prader–Willi syndrome .

Type 1 Diabetes Research (2026)

A groundbreaking Phase 2 randomized controlled trial published in Diabetes Care (January 2026) investigated tirzepatide in adults with type 1 diabetes and BMI >30 kg/m² :

• Duration: 12 weeks

• Dosing: 2.5 mg for 4 weeks, then 5.0 mg for 8 weeks

• Mean weight change: -10.3 kg tirzepatide vs. -0.7 kg placebo (p < 0.0001)

• Weight loss achievements: 100% of tirzepatide participants achieved ≥5% loss; 45% achieved ≥10% loss

• HbA1c improvement: Mean difference -0.4% vs. placebo (p = 0.05)

• Insulin dose reduction: -35.1% total daily insulin vs. placebo (p = 0.0002)

• Safety: No significant adverse events

This represents the first study of tirzepatide in type 1 diabetes, opening new research directions .

---

PRODUCT SPECIFICATIONS

Our advantage: We exceed industry standards on purity and endotoxin levels, with third-party verification for each batch. Our specifications align with pharmaceutical-grade requirements while maintaining research-accessible pricing.

---

 ANALYTICAL TESTING: PROVEN BY DATA

As peptide-based therapeutics evolve in structural complexity, comprehensive analytical characterization becomes indispensable to confirm identity, purity, and critical quality attributes . Every batch of our tirzepatide undergoes rigorous quality control testing based on industry best practices:

1. Identity Confirmation

• Retention time comparison to reference standard by LC/UV

• Molecular mass determination by LC/MS

• Sequence determination by LC/MS/MS

• Amino acid analysis

2. Purity and Impurity Assessment

• Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification

• Visual chromatogram provided

• Related substances analysis: 2-5% (tailored to specifications)

• 2D-LC for complex impurity profiling

3. Mass Spectrometry (MS)

• Confirms exact molecular weight (~4813.45 g/mol)

• Verifies sequence integrity

• Ensures correct structural identity

• Quantification using Agilent 6495D Triple Quadrupole LC/MS systems

4. Peptide Content Determination

• Assay (peptide content): >75%

• Accounts for counterions and moisture

• Ensures accurate experimental dosing

5. Residual Solvents and Counterions

• Residual Trifluoroacetic acid: <0.25%

• Residual organic solvents: ICH guidelines or dosage dependent

• Mass balance: 95-105%

6. Bioburden and Endotoxin Testing

• Bioburden: According to USP or EP guidelines

• Endotoxin: According to USP or EP guidelines or dosage dependent

• Ensures safety for research applications

---

STABILITY AND HANDLING

Storage Requirements

Critical handling notes:

• Store in a cool, dry place protected from light

• Keep package closed when not in use

• Allow vial to reach room temperature before opening to minimize condensation

• After reconstitution with bacteriostatic water, remains potent in refrigerator for weeks

• Avoid repeated freeze-thaw cycles

Reconstitution Guidelines

For research purposes, tirzepatide is soluble in sterile water, bacteriostatic water, or aqueous buffers.

For 5mg vial:

• Add 1-2 mL bacteriostatic water = 2.5-5 mg/mL concentration

Recommended protocol:

1. Centrifuge vial briefly to ensure powder is at bottom

2. Reconstitute with sterile water or bacteriostatic water

3. Gently swirl—do not vortex (peptides are fragile)

4. For extended studies, prepare sterile aliquots to avoid repeated freeze-thaw cycles

5. Allow complete dissolution before use; solution should be clear with no particulates

---

TIRZEPATIDE VS. OTHER GLP-1 ANALOGS

---

SAFETY AND REGULATORY STATUS

Current Regulatory Status

Tirzepatide is FDA-approved for:

• Type 2 diabetes (as Mounjaro®, 2022)

• Obesity (as Zepbound®, 2023)

Our tirzepatide is sold for laboratory research purposes only. It is:

• Not for human consumption

• Not for diagnostic or therapeutic use without appropriate licensing

• For in vitro research and analytical applications

• For qualified researchers only

Safety Profile from Clinical Trials

Based on extensive clinical trial data :

A 2025 network meta-analysis of 13 RCTs (14,007 participants) confirmed that tirzepatide has fewer serious adverse events than insulin (RR 0.71-0.77) and lower hypoglycemia risk (RR 0.44-0.50), though gastrointestinal events are increased .

Important Safety Considerations

• Pancreatitis risk: Acute pancreatitis is a recognized side effect; product information has been updated to highlight the potential risk, including rare reports of necrotizing and fatal pancreatitis

• Thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma

• Gallbladder disease: Increased risk observed in clinical trials

Research Use Only

Our tirzepatide is sold for laboratory research purposes only. It is:

• Not for human consumption

• Not for diagnostic or therapeutic use

• For in vitro research and analytical applications

• For qualified researchers only

• Requires age verification (21+) for purchase

---

ORDERING INFORMATION

Each order includes:

• Batch-specific Certificate of Analysis

• HPLC chromatogram (upon request)

• Mass spectrometry confirmation (upon request)

• Lot number for full traceability

• Vacuum-sealed, desiccated packaging

• Temperature-stable international shipping

Shipping to USA: 5–7 business days (typical)

---

TIRZEPATIDE FREQUENTLY ASKED QUESTIONS

---

Q: What is the difference between tirzepatide and semaglutide?

A: Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide is a selective GLP-1 receptor agonist. In head-to-head trials, tirzepatide demonstrated superior weight loss: -20.2% vs. -13.7% at 72 weeks in SURMOUNT-5 . Tirzepatide’s additional GIP receptor activation may contribute to greater efficacy through direct effects on adipose tissue and enhanced energy expenditure .

---

Q: What is the CAS number for tirzepatide?

A: The CAS number is 2023788-19-2.

---

Q: What is the molecular weight of tirzepatide?

A: The molecular weight is approximately 4813.45 g/mol (C₂₂₅H₃₄₈N₄₈O₆₈).

---

Q: What purity should I expect for research-grade tirzepatide?

A: Research-grade tirzepatide should be ≥98-99% purity by HPLC analysis . Pinecrest’s tirzepatide is ≥99% with full documentation, including third-party testing for identity, purity, and endotoxicity.

---

Q: How does tirzepatide achieve once-weekly dosing?

A: Tirzepatide incorporates a C20 fatty diacid moiety that binds to albumin in the bloodstream, creating a circulating reservoir that slowly releases active peptide. This extends the half-life sufficiently for once-weekly administration .

---

Q: What are the main research applications for tirzepatide?

A: Tirzepatide is primarily studied for :

• Obesity and metabolic research

• Type 2 diabetes mechanisms

• Type 1 diabetes (emerging research)

• Adipose tissue biology

• Cardiovascular risk factors

• Genetic obesity models (MC4R deficiency)

• Weight maintenance and regain prevention

---

Q: How should tirzepatide be stored?

A: Lyophilized tirzepatide should be stored at -20°C to -80°C for long-term stability, or at ≤25°C sealed away from heat, light, and moisture for short-term storage . Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.

---

Q: What is the significance of the GIP-based backbone?

A: Tirzepatide’s GIP-based backbone provides inherent stability and optimal receptor interactions. It has greater affinity for GIP receptors than GLP-1 receptors, creating a balanced dual agonism profile that may be responsible for its unprecedented efficacy .

---

Q: Is tirzepatide approved for type 1 diabetes?

A: No, tirzepatide is not FDA-approved for type 1 diabetes. However, a Phase 2 randomized controlled trial published in 2026 demonstrated significant benefits in adults with type 1 diabetes and obesity, including 8.8% weight loss, improved HbA1c, and 35% reduction in insulin requirements . This represents an active area of research.

---

Q: What is the SURMOUNT clinical trial program?

A: SURMOUNT is the comprehensive Phase 3 clinical trial program investigating tirzepatide for obesity. Trials include SURMOUNT-1 (obesity without diabetes), SURMOUNT-2 (obesity with type 2 diabetes), SURMOUNT-3 and -4 (weight maintenance), SURMOUNT-5 (head-to-head vs. semaglutide), and SURMOUNT-J (Japanese population) .

---

RECENT RESEARCH HIGHLIGHTS (2025-2026)

---

WHAT RESEARCHERS SAY

Dr. Alan Richards – Richards Research Institute, Boston

*”Our lab studies metabolic pathways in obesity and diabetes models. Tirzepatide’s dual agonist mechanism offers a unique tool for understanding how GIP and GLP-1 pathways interact. The 2026 MC4R-deficient mouse study confirms the translational relevance of preclinical models. Pinecrest’s product has been consistently pure with excellent documentation across multiple orders.”*

Kevin O’Brien – O’Brien Distributing, Chicago

*”Tirzepatide is our most requested peptide following the SURMOUNT-5 results and the recent type 1 diabetes study. Researchers appreciate its well-characterized mechanism and the extensive clinical data supporting its effects. Pinecrest’s quality and third-party testing give my clients confidence in their research.”*

Dr. Susan Walters – Walters Clinical Research, Cleveland

“The distinction between dual and single agonism is critical for our research into metabolic disease mechanisms. Having access to well-documented, high-purity tirzepatide with full analytical characterization—including LC/MS confirmation and impurity profiling—is essential for reproducible results.”

---

READY TO ORDER TIRZEPATIDE PEPTIDES FOR SALE?

Questions about tirzepatide for your research? Email us.

sales@pinecrestpeptides.com
Response time: Within 4 hours

---

ORDER TIRZEPATIDE PEPTIDES FOR SALE TODAY

The revolutionary dual GIP/GLP-1 agonist. 99% pure. Manufacturer-direct. Ready to ship to USA labs.